RxDoctor Payments Data

Ali Tajik, MD

Family Medicine · Anaheim, CANPI 1629020268

Payments from drug & device makers

$2,642in general payments, 2019–2025

Across 149 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$571
  • Amgen$536
  • Johnson & Johnson$355
  • Pfizer$215
  • Lilly USA, LLC$176
  • Novo Nordisk$75
  • plus $715 from 18 others

What the payments were for

  • Food & beverage$2,642100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,642 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$176,899
Medicare patients
281
Services billed
1,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate89$96,695
EliquisApixaban96$84,914
IngrezzaValbenazine Tosylate20$78,890
LinzessLinaclotide72$72,767
JardianceEmpagliflozin27$40,818
OzempicSemaglutide35$39,853
EntrestoSacubitril/Valsartan29$27,623
ProliaDenosumab15$24,501
Sevelamer Hcl11$22,497
XareltoRivaroxaban20$21,199
FarxigaDapagliflozin Propanediol22$18,491
VascepaIcosapent Ethyl39$13,732
Breo ElliptaFluticasone/Vilanterol22$13,023
TrulicityDulaglutide11$10,076
MyrbetriqMirabegron11$9,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$66$96,69589 claims
PfizerEliquis$215$84,91496 claims
AbbVieLinzess$50$72,76772 claims
Boehringer IngelheimJardiance$32$40,81827 claims
Novo NordiskOzempic$75$39,85335 claims
NovartisEntresto$571$27,62329 claims
AstraZenecaFarxiga, Lokelma$39$25,06538 claims
AmgenProlia$536$24,50115 claims
Johnson & JohnsonXarelto$355$21,19920 claims
GSKBreo Ellipta$64$13,02322 claims
Lilly USA, LLCTrulicity$176$10,07611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →